Inhibitory Impact of the Amino Benzoic Derivative DAB-2-28 on the Process of Epithelial–Mesenchymal Transition in Human Breast Cancer Cells

Inhibitory Impact of the Amino Benzoic Derivative DAB-2-28 on the Process of Epithelial–Mesenchymal Transition in Human Breast Cancer Cells

Macrophage-mediated inflammation is known to be involved in the epithelial–mesenchymal transition (EMT) of various types of cancer. This makes macrophage-derived inflammatory factors prime targets for the development of new treatments. This study uncovers the therapeutic potential and action mechani...

Full description

Saved in:

Bibliographic Details
Main Authors:	Laurie Fortin, Julie Girouard, Yassine Oufqir, Alexis Paquin, Francis Cloutier, Isabelle Plante, Gervais Bérubé, Carlos Reyes-Moreno
Format:	Article
Language:	English
Published:	MDPI AG 2025-08-01
Series:	Molecules
Subjects:	inflammation luminal breast cancer macrophages <i>para</i>-aminobenzoic acid (PABA) small molecules triple-negative breast cancer
Online Access:	https://www.mdpi.com/1420-3049/30/15/3284
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of para-aminobenzoic acid on morphologic changes of the retina in the rd10 mouse model of retinitis pigmentosa
by: Galbinur T., et al.
Published: (2014-07-01)

LYMPHOGENIC METASTASIS IN LUMINAL-TYPE A BREASR CANCER
by: M. V. Zavjalova, et al.
Published: (2016-02-01)

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity
by: Stefan Prekovic, et al.
Published: (2023-10-01)

Increasing rates of early-onset Luminal A breast cancers correlate with binge drinking patterns
by: Jianjiu Chen, et al.
Published: (2024-10-01)

ADJUVANT CHEMOTHERAPY OF PRIMARY OPERABLE LUMINAL B BREAST CANCER WITHOUT OVEREXPRESSION OF HER2/NEU IN POSTMENOPAUSAL WOMEN: YES OR NO?
by: Yu. S. Shatova, et al.
Published: (2017-12-01)

Immunological and molecular genetic characteristics of luminal B breast cancer: a literature review
by: D. A. Ryabchikov, et al.
Published: (2017-02-01)

Prognostic value of FGFR2 in ER-positive breast cancer is influenced by the profile of stromal gene expression: an in silico analysis based on TCGA data
by: Julia M. Sołek, et al.
Published: (2025-01-01)

Role of proteasome system in prognosis of breast cancer progression
by: E. E. Shashova, et al.
Published: (2018-09-01)

MiR-101-3p and miR-106b-5p roles in EMT pathway: prognostic and therapeutic insights for luminal breast cancer
by: Gehad Tarek, et al.
Published: (2025-07-01)

ROLE OF MORPHOLOGICAL AND GENETIC STRUCTURAL CHARACTERISTICS OF ESTROGEN RECEPTOR ALPHA IN THE DEVELOPMENT OF RESISTANCE TO ENDOCRINOTHERAPY WITH TAMOXIFEN IN PATIENTS WITH LUMINAL BREAST CANCER
by: Е. М. Slonimskaya, et al.
Published: (2016-02-01)

MORPHOLOGICAL STUDY OF LUMINAL BREAST CANCER
by: M. V. Zavyalova, et al.
Published: (2016-02-01)

Knockdown of PVT1 inhibits cell proliferation in luminal and basal-like breast cancer subtypes by activating LATS2/Hippo signaling pathway
by: Hai-Bo Zhang, et al.
Published: (2025-07-01)

WWP1 targeting PTEN for polyubiquitination to promote bone metastasis of luminal breast cancer
by: Hao Jiang, et al.
Published: (2024-12-01)

Genetic association of toll like receptors and breast cancer: a novel approach toward countering the breast cancer tumor invasiveness and recurrence
by: Avishek Das, et al.
Published: (2025-04-01)

Construction and validation of acetylation-related gene signatures for immune landscape analysis and prognostication risk prediction in luminal breast cancer
by: Mengdi Zhu, et al.
Published: (2025-07-01)

The Analysis of Plasma Proteomics for Luminal A Breast Cancer
by: Meimei Zhao, et al.
Published: (2024-12-01)

Prognostic Importance of PTEN and P53 in Aggressive Luminal A Subtype Breast Cancers
by: Öykü Dila Gemci, et al.
Published: (2025-07-01)

Antifungal and Antibiofilm Activities of 2-Aminobenzoic Acid Derivatives Against a Clinical Ocular <i>Candida albicans</i> Isolate for Biomedical Applications
by: Francesco Petrillo, et al.
Published: (2025-04-01)

Synthesis of Novel Benzocaine and Procaine Glycodrugs
by: Natividad Bejarano Rengel, et al.
Published: (2024-11-01)

ROLE OF TRANSFORMING GROWTH FACTOR RECEPTOR B I TYPE (TGF-BRI) IN THE PROGRESSION OF THE LUMINAL BREAST CANCER SUBTYPE
by: N. N. Babyshkina, et al.
Published: (2017-06-01)

SNORA47 affects stemness and chemotherapy sensitivity via EBF3/RPL11/c-Myc axis in luminal A breast cancer
by: Qilin Han, et al.
Published: (2025-04-01)

ROR1 and BMI-1 proteins as potential predictors of the effectiveness of hormone therapy in luminal breast cancer
by: V. O. Tarakanova, et al.
Published: (2022-06-01)

Features of gene polymorphism associations linked with sex hormone binding globulin level and breast cancer of various molecular biological subtypes
by: K. N. Pasenov, et al.
Published: (2024-01-01)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
by: Eduardo Terán, et al.
Published: (2024-09-01)

Oncogene activated human breast luminal progenitors contribute basally located myoepithelial cells
by: Katharina Theresa Kohler, et al.
Published: (2024-12-01)

The effect of rehabilitation on quality of life in female breast cancer survivors in Iran
by: Poorkiani M, et al.
Published: (2010-12-01)

NEO adjuvant chemotherapy in breast cancer: What have we learned so far?
by: Raut Nirmal, et al.
Published: (2010-03-01)

Significance and possible causes of hormone receptor expression loss in metastatic breast cancer. Phenotypic evolution of luminal <i>BRCA1</i>-associated breast cancer to triple negative subtype in lung metastasis and PARP inhibition strategy in early-line therapy
by: A. I. Stukan, et al.
Published: (2022-12-01)

Targeting a cell state common to triple‐negative breast cancers
by: Markus K Muellner, et al.
Published: (2015-02-01)

Expression of E- and N-cadherins in tumor in luminal, primary operable breast cancer without Her2/neu overexpression in postmenopausal women as a prognostic factor
by: V. V. Tokmakov, et al.
Published: (2020-12-01)

Targeting SOST using a small-molecule compound retards breast cancer bone metastasis
by: Lisha Sun, et al.
Published: (2022-12-01)

Polymorphic variants of the <i>hOGG1, APEX1, XPD, SOD2</i>, and <i>CAT</i> genes involved in DNA repair processes and antioxidant defense and their association with breast cancer risk
by: А. А. Timofeeva, et al.
Published: (2024-07-01)

Phytosomes Loaded with Mastoparan-M Represent a Novel Strategy for Breast Cancer Treatment
by: Zhao H, et al.
Published: (2025-01-01)

Ethanolic Extract of <i>Averrhoa carambola</i> Leaf Has an Anticancer Activity on Triple-Negative Breast Cancer Cells: An In Vitro Study
by: Oscar F. Beas-Guzmán, et al.
Published: (2024-12-01)

Studies on Anti-Cancer Agents from Natural Resources with Special Reference to <i>Cannabis sativa</i> and <i>Datura metel</i> L.
by: Shrimanti Chakraborty, et al.
Published: (2024-11-01)

The outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysis
by: Albin Bengtsson, et al.
Published: (2025-08-01)

Quantitative Analysis of Isoflavones from <i>Fabaceae</i> Species and Their Chemopreventive Potential on Breast Cancer Cells
by: Wojciech Paździora, et al.
Published: (2025-05-01)

Treatment of luminal HER2-negative breast cancer: opinion of experts
by: E. V. Artemeva, et al.
Published: (2024-06-01)

Studying GATA3, FOXA1, and ELF5 transcription factors in the evaluation of prognosis in luminal breast cancer patients
by: S. V. Vtorushin, et al.
Published: (2021-01-01)

Image J as the quantification tool in endosonography strain elastography may be reflected in the disturbance of endocrine pancreatic dysfunction
by: Ken Nakamura, et al.
Published: (2025-04-01)